Table 2

Eligibility criteria

Inclusion criteriaExclusion criteria
  1. Adults (>18 years old)

  2. Clinical diagnosis of SARS-CoV2 infection with rtPCR confirmation

  3. Disease severity that has the indication of immunomodulation therapy with interleukin-6 antagonist: acute respiratory failure that requires invasive, noninvasive ventilation, Noninvasive O2 therapy or high flow nasal oxygen therapy with the following parameters: FiO2 >0.4, flow >30 L/min and CRP >75 mg/L

  1. The patient had previously been administered one of the following immunomodulating drugs: anakinra, tocilizumab, sarilumab

  2. Presence of any condition or drug in the medical history that can lead to immunosuppression

  3. Suspicion of infection (active tuberculosis, bacterial, viral, fungal) or level of procalcitonin higher than 0,5 ng/mL at the enrolment of the patient

  4. The number of thrombocytes lower than 50×109 /L

  5. More than>120 hours passed between the admission to the ICU and the administration of an interleukin-6 antagonist

  6. Administration of any of the following drugs the week before or during the study: fibrinolytic therapy, factor products (PCC, ATIII, FVIIa, FXIII), fibrinogen, desmopressin, tranexamic acid, blood products (fresh frozen plasma, thrombocyte concentrate)

  7. Pregnancy

  8. The patient or his legal guardian does not sign the consent

  • ATIII, antithrombin III concentrate; CRP, C reactive protein; FiO2: fraction of inspired oxygen; FVIIa, factor VIIa concentrate; FXIII, factor XII concentrate; PCC, prothrombin complex concentrate; rtPCR, reverse transcription PCR.